CB-NK-TGF-βR2-/NR3C1

N/A

Report date: 2022/12/31 17:30:02

Base Information

Drug NameCB-NK-TGF-βR2-/NR3C1
Drug Alias NameCB-NK-TGF-βR2-/NR3C1-
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > Natural killer cell therapy
Mechanisms of ActionNatural killer cell replacements
TargetsNot applicable
Therapy Area/IndicationsColonic Neoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesMd Anderson Cancer Center Orlando
China Registration ClassN/A

Develop Information

Active CompaniesMd Anderson Cancer Center OrlandoThe University Of Texas MD Anderson Cancer Center
Inactive CompaniesN/A
Active IndicationsColonic Neoplasms
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A